Latest Ratios: P/E Ratio 0.0x · EV/EBITDA N/A · ROE -681.6%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $117 | $7M | $13.2B | — | — | — | — | — | — | — |
| Enterprise Value | $6M | $13M | $13.2B | — | — | — | — | — | — | — |
| P/E Ratio → | 0.00 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.04 | 2108.72 | 98346.73 | — | — | — | — | — | — | — |
| P/B Ratio | 0.00 | 1.70 | 1590.20 | 82192.04 | 826971.03 | 4364082.69 | 1178195.12 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4013.99 | 98392.16 | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 8.4% | 8.4% | -368.0% | -17.3% | 17.9% | 25.8% | — | — | — | — |
| Operating Margin | -612542.2% | -612542.2% | -20796.4% | -4039.6% | -2728.9% | -39925.2% | — | — | — | — |
| Net Profit Margin | -1305608.8% | -1305608.8% | -25708.8% | -5018.9% | -2961.3% | -44148.6% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -681.6% | -681.6% | -283.1% | -304.7% | -359.4% | -437.6% | -224.3% | — | — | — |
| ROA | -171.4% | -171.4% | -89.8% | -117.1% | -201.8% | -311.6% | -138.4% | -4873.5% | -8086.2% | -852.0% |
| ROIC | -120.2% | -120.2% | -86.1% | -97.8% | -297.4% | -670.8% | — | — | — | — |
| ROCE | -300.3% | -300.3% | -203.2% | -202.2% | -252.9% | -336.5% | -196.8% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.75 | 1.75 | 0.84 | 1.14 | 0.65 | 0.46 | 0.17 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 1.54 | 0.73 | 1.13 | 0.12 | -0.31 | -0.79 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -0.04 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -16.92 | -16.92 | -3.76 | -4.07 | -11.10 | -22.92 | -28.51 | -3018.55 | -70.32 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.31 | 0.31 | 0.09 | 0.27 | 1.30 | 2.61 | 8.99 | 0.00 | 0.07 | 0.42 |
| Quick Ratio | -0.16 | -0.16 | 0.08 | 0.24 | 1.04 | 2.47 | 8.99 | 0.00 | 0.07 | 0.42 |
| Cash Ratio | 0.07 | 0.07 | 35.59 | 0.00 | 0.76 | 2.18 | 8.56 | 0.00 | 0.07 | 0.42 |
| Asset Turnover | — | 0.00 | 0.00 | 0.01 | 0.09 | 0.01 | — | — | — | — |
| Inventory Turnover | 0.00 | 0.00 | 55.80 | 1.02 | 0.81 | 0.16 | — | — | — | — |
| Days Sales Outstanding | — | — | 3138.77 | 3311.23 | 206.39 | 2049.75 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 100.0% | 100.0% | 0.0% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 100.0% | 100.0% | 0.0% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $37355 | $13177 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Imminent insolvency and dilution
According to recent market data, Aditxt trades at a price-to-sales multiple of 0.10, a figure that, based on reported figures, suggests the market has largely abandoned the company's diagnostic revenue model in favor of pricing it as a speculative, distressed option on its underlying intellectual property.
The lack of meaningful P/E or EV/EBITDA multiples underscores the company's inability to generate positive earnings or operational cash flow. Investors should monitor whether this low valuation represents a genuine floor or if the market is correctly pricing in the high probability of further equity dilution required to sustain the firm's research pipeline.
As reported in financial statements, Aditxt's ROIC has consistently remained in deep negative territory, with recent quarterly figures showing a -120.3% return, which indicates that the company is currently destroying shareholder capital rather than compounding it through its licensed immune-tolerance technology development efforts.
The persistent decay in returns on invested capital suggests that the firm's R&D expenditures have yet to yield any tangible commercial or clinical milestones. This trend warrants further investigation into whether the current capital allocation strategy can ever achieve a positive return profile without a fundamental shift in the business model.
Based on EDBL's reported figures, the company's cash conversion cycle has exhibited extreme volatility, frequently reaching negative values such as -44310 days in 2026Q1, which suggests that the firm lacks a stable or predictable operational rhythm in managing its payables and receivables relative to its minimal revenue.
The erratic nature of these efficiency metrics appears to be a byproduct of the company's near-zero revenue scale rather than effective working capital management. Analysts should interpret these figures as a sign of operational distress, as the firm struggles to maintain basic administrative functions while its core diagnostic business remains dormant.
As indicated by recent SEC filings, Aditxt's current ratio has deteriorated to a precarious 0.06, a level that suggests the company possesses insufficient liquid assets to meet its immediate short-term obligations without relying on external financing or further dilutive capital raises to maintain its ongoing operations.
This liquidity position appears highly vulnerable to even minor operational shocks, leaving the firm with virtually no margin for error. Investors should monitor the company's cash burn rate closely, as the current trajectory suggests that the firm may face a liquidity crisis in the near term.
The most commonly misapplied metric for Aditxt is the price-to-book ratio, which, at 0.00, obscures the reality that the company's book value is heavily distorted by accumulated losses and intangible assets that may hold little liquidation value in a distressed clinical development environment.
Instead of relying on book value, analysts should focus on the cash-to-burn ratio to assess the firm's runway, as the company's true value is tied to its ability to reach clinical milestones before exhausting its remaining capital. Using traditional valuation multiples for a pre-revenue entity with negative equity may lead to a fundamental misunderstanding of the firm's insolvency risk.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADTX stock.
Aditxt, Inc.'s current P/E ratio is 0.0x.
Aditxt, Inc.'s return on equity (ROE) is -681.6%. The historical average is -321.8%.
Based on historical data, Aditxt, Inc. is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.
Aditxt, Inc. has 8.4% gross margin and -612542.2% operating margin.